Fiche publication
Date publication
mars 2018
Journal
The New England journal of medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi
Tous les auteurs :
Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukovinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T
Lien Pubmed
Résumé
Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer. However, since oxaliplatin is associated with cumulative neurotoxicity, a shorter duration of therapy could spare toxic effects and health expenditures.
Mots clés
Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, Capecitabine, administration & dosage, Chemotherapy, Adjuvant, Clinical Trials, Phase III as Topic, Colonic Neoplasms, drug therapy, Disease-Free Survival, Drug Administration Schedule, Female, Fluorouracil, administration & dosage, Humans, Intention to Treat Analysis, Leucovorin, administration & dosage, Male, Medication Adherence, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Nervous System Diseases, chemically induced, Organoplatinum Compounds, administration & dosage, Proportional Hazards Models, Prospective Studies, Randomized Controlled Trials as Topic, Young Adult
Référence
N. Engl. J. Med.. 2018 Mar 29;378(13):1177-1188
